Bevacizumab (avastin) and imatinib mesylate (gleevec) (DrugBank: Bevacizumab, Imatinib)
12 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
28 | Systemic amyloidosis | 0 |
34 | Neurofibromatosis | 0 |
35 | Pemphigus | 0 |
46 | Malignant rheumatoid arthritis | 0 |
51 | Scleroderma | 0 |
85 | Idiopathic interstitial pneumonia | 0 |
86 | Pulmonary arterial hypertension | 0 |
87 | Pulmonary veno-occlusive disease | 1 |
88 | Chronic thromboembolic pulmonary hypertension | 0 |
89 | Lymphangioleiomyomatosis | 0 |
162 | Pemphigoid | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00891527 (ClinicalTrials.gov) | October 2008 | 30/4/2009 | Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis | Adjunct Targeted Biologic Inhibition in Children With Multivessel Intraluminal Pulmonary Vein Stenosis | Pulmonary Veno Occlusive Disease | Drug: Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec) | Boston Children's Hospital | NULL | Completed | N/A | N/A | All | 50 | Phase 1;Phase 2 | United States |